Argus® II Retinal Stimulation System Feasibility Protocol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00407602|
Recruitment Status : Completed
First Posted : December 5, 2006
Results First Posted : December 30, 2021
Last Update Posted : January 20, 2022
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
Investigational Phase of the Study:
The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with retinitis pigmentosa.
Post-Approval Phase of the Study:
To collect post-approval data in order to monitor the ongoing safety and reliability of the Argus II System
|Condition or disease||Intervention/treatment||Phase|
|Retinitis Pigmentosa||Device: Implant of Argus II Retinal Prosthesis||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Argus® II Retinal Stimulation System Feasibility Protocol|
|Study Start Date :||September 2006|
|Actual Primary Completion Date :||December 31, 2019|
|Actual Study Completion Date :||December 31, 2019|
Implant of Argus II Retinal Prosthesis
This is a single group study where the status and performance of the implanted eye prior to surgery serves as the comparator.
Device: Implant of Argus II Retinal Prosthesis
epiretinal implantation of device
- Visual Acuity [ Time Frame: 10 years ]Grating Visual Acuity is performed at Baseline and at various timepoints throughout the study. As of the 10 year final testing, the total number of subjects that were able to score on the logMAR scale are indicated below. The device has a scale from 1.6 to 2.9 logMAR. Maximum likelihood estimation of visual acuity is based on BEST-PEST algorithm.
- Number of Participants With Adverse Events [ Time Frame: 10 years ]Evaluate ocular adverse events reported for all subjects from day of implant through 10 years of study participation
- Massof Activity Inventory [ Time Frame: 3 years ]The Massof Activity Inventory measures changes in ability to perform activities of daily living in terms of Goals and Tasks in logits (log-odds units). A logit scale is an equal interval linear scale that represents probability values in terms of real numbers. There is no minimum or maximum scale used in this testing. In this case, a Rasch distribution (using an Andrich rating model) was used to find the maximum likelihood of difficulty of achieving Goals and Tasks, represented in logits. The change in mean logit value between baseline and the 36Month visit for each subject are provided below along with the 95% confidence interval (CI) for the change. A positive change in the Goals or Tasks score which is greater than 0.2 (with a CI less than the mean logit value), is interpreted as a clinically significant increase in functional ability (better outcome).
- Quality of Life - Tasks for Daily Living [ Time Frame: 3 years ]Quality of life is being measured using the VisQOL survey. This instrument, developed by researchers at the University of Melbourne, Australia, is a vision and quality of life-related utility measure intended to evaluate healthcare interventions for the visually impaired. The utility score is a preference-based measure of vision-related quality of life (Dimension 7 score (Health Dimension Score (1=Best, 0=Worst)). It measures subjective quality of life on a scale of 0 to 1, where 0 represents worst possible quality of life and 1 represents perfect quality of life.
- Orientation and Mobility [ Time Frame: 5 years ]Argus II System for orientation and mobility, each subject completed two tests (walking to a high-contrast "door" on the wall and following a straight line on the floor) at various timepoints throughout the study. Accuracy (percent of trials where the subject successfully reached the target) was measured with the device system ON and system OFF. Average % success rates across the analysis population are provided for each modality and for each test at the 60 month time point.
- Visual Function [ Time Frame: 10 years ]Square localization (SL) and Direction of Motion (DOM) testing performed at specific protocol intervals. SL tests ability of subjects to locate high-contrast square on black screen. DOM tests ability of subjects to determine the direction a white bar is moving over a black screen. Each test is performed with the system ON and then compared to performance with the system OFF. Number of subjects who performed significantly better with the system ON is indicated below.
- Stability of Implant - 5 Years Post Implant [ Time Frame: 5 years ]Stability of electrode array on the retina. Qualitative review of imaging: retinal and array landmarks compared from all time points post implant.
- Device Reliability [ Time Frame: 10 years ]Number of participants with functional devices 10 years post implant
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- A confirmed history of retinitis pigmentosa (all centers) or outer retinal degeneration (France, U.K., Switzerland, Mexico only) with remaining visual acuity of bare light perception (all centers) or 2.3 logMAR (France, U.K., Switzerland, Mexico only) or worse in both eyes.
- Functional ganglion cells and optic nerve as determined by a measurable electrically evoked response or documented light perception.
- A history of former useful form vision in the worse-seeing eye.
- Must be at least the following age at the time of enrollment: 25 (USA, Switzerland) or 18 (France, U.K., and Mexico) years old
- Must reside within 2 hours (USA, UK and Mexico) or 3 hours (France and Switzerland) distance (by ground transportation) of the investigational site.
- Must be willing and able to comply with the protocol testing and follow-up requirements.
Optic Nerve disease
- History of glaucoma
- Optic neuropathy or other confirmed damage to optic nerve or visual cortex damage
Diseases or conditions that effect retinal function including but not limited to:
- Central retinal artery/vein occlusion (CRAO or CRVO)
- End-stage diabetic retinopathy
- Retinal detachment or history of retinal detachment
- Infectious or inflammatory retinal diseases
- Diseases or conditions that prevent adequate visualization of the retina including, but not limited to corneal degeneration that cannot be resolved before implant.
- Diseases or conditions of the anterior segment that prevent the ability to adequately perform the physical examination including but not limited to trauma or lid malpositions.
- Diseases of the ocular surface including but not limited to keratitis sicca.
- An ocular condition that predisposes the subject to eye rubbing.
Any disease or condition that prevents understanding or communication of informed consent, study demands, and testing protocols, including:
- Cognitive decline including diagnosed forms of dementia and/or progressive neurological disease
- Psychiatric Disease including diagnosed forms of depression
- Does not speak a principal language associated with the region
- Deafness or selective frequency hearing loss that prevents hearing device alarms and alerts.
- Subject has another active implantable device (e.g. cochlear implant), or any form of metallic implant in the head
- Conjunctival thinning which may predispose the subject to conjunctival erosion in the area where the implant will be installed extra-ocularly.
- Subject is participating in another investigational drug or device study that may conflict with the objectives, follow-up or testing of this study
- Any health concern that makes general anesthesia inadvisable.
- Subject has unrealistic expectations of the implant.
- Known allergy or contraindication to anticipated pre-operative, intra-operative or post-operative medications.
- Conditions likely to limit life to less than 1 year from the time of screening.
- Diseases or conditions that, in the judgement of the surgeon, impede the ability to implant the device or would prevent the system from functioning for the duration of the study (e.g. strabismus)
- Axial eye length <21.5 mm or >26.0 mm in the implanted eye as measured by ultrasound (US only)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00407602
|United States, California|
|Doheny Eye Institute|
|Los Angeles, California, United States, 90033|
|University of California San Francisco|
|San Francisco, California, United States, 94143|
|United States, Maryland|
|Johns Hopkins, Wilmer Eye Institute|
|Baltimore, Maryland, United States, 21205|
|United States, New York|
|Columbia University, Department of Ophthalmology, Edward S. Harkness Eye Institute|
|New York, New York, United States, 10032|
|United States, Pennsylvania|
|University of Pennsylvania, Scheie Eye Institute|
|Philadelphia, Pennsylvania, United States, 19104|
|Wills Eye Hospital|
|Philadelphia, Pennsylvania, United States, 19107|
|United States, Texas|
|Retina Foundation of the Southwest|
|Dallas, Texas, United States, 75231|
|Centre d'Investigation Clinique, Service d'Ophtalmologie, Quinze-Vingts National Eye Hospital, 28 rue de Charenton, 75557 Cedex 12|
|Puerta de Hierro, Centro Medico, Centro de Retina|
|Zapopan, Jalisco, Mexico, 51116|
|Clinique d'Ophthalmologie Hopitaux, Universitaires de Geneve 22 rue Alcide Jentzer 1205|
|Moorfields Eye Hospital, Vitreoretinal Research Unit|
|London, United Kingdom, EC1V 2PD|
|Manchester Royal Eye Hospital|
|Manchester, United Kingdom|
|Study Director:||Anne-Marie Ripley||Second Sight Medical Products|
Documents provided by Second Sight Medical Products:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
|Responsible Party:||Second Sight Medical Products|
|Other Study ID Numbers:||
National Eye Institute (NEI) ( Other Grant/Funding Number: 2R01EY012893-06A1 )
|First Posted:||December 5, 2006 Key Record Dates|
|Results First Posted:||December 30, 2021|
|Last Update Posted:||January 20, 2022|
|Last Verified:||January 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
outer retinal degeneration
Eye Diseases, Hereditary
Genetic Diseases, Inborn